Breast Cancer

Adding Ibrance to maintenance therapy extends the time some patients with metastatic breast cancer live without their disease progressing.

I’m preparing for something I once only dreamed about: my final visit to the cancer treatment center.

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Researchers found that nearly two-thirds of patients with HER2-positive metastatic breast cancer did not receive the guideline-recommended standard of care treatment.

Dr. Anne Peled, a two-time breast cancer survivor, underwent a sensation-preserving mastectomy, a procedure she co-developed.

Dr. Anne Peled shares advice for patients and dispelled myths related to cancer survivorship.

If you’re struggling out there, feeling a little broken inside, I see you. And if you’re not, man, I wish I were you.

This weekend, January 30 - February 1, join thousands of runners, walkers, survivors and spectators for the 19th Annual DONNA Marathon Weekend.

Among patients with advanced breast cancer, levels of circulating tumor DNA before treatment may predict their response to targeted therapy.

For Ashliann Mazeika, a diagnosis at 24 led to a decade-long treatment journey affirmed by the Breast Cancer Index test.

MammaPrint and BluePrint tests may help identify HR+/HER2– early-stage breast cancer patients likely to benefit from anthracycline-based chemotherapy.

Dr. Anne Peled co-developed the sensation-preserving mastectomy she received after her second diagnosis of breast cancer.

The FDA accepted a new drug application for gedatolisib for patients with HR+, HER2-, PIK3CA wild-type advanced breast cancer.

There’s no moral to my story, except to say I’m grateful for good doctors and modern medicine.

I share how choosing what to do with my hair during treatment helped me reclaim control and redefine empowerment.

Tukysa may be a patient-friendly option as a first line maintenance treatment for HER2-positive breast cancer, as Dr. Erika Hamilton explained.

Dr. Erika Hamilton sat down for an interview with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 highlight patient care advances.

My dog Chloe had a lump that scared us, but it turned out to be a benign lipoma. Surgery went well, and she’s now fully healed and playful again.

Breast cancer survivors who continue to deal with high-risk factors in a remaining breast need to be proactive about medical protocols that fit a high-risk survivor’s needs.

CURE spoke with Dr. Natalie S. Berger for the latest episode of the "Cancer Horizons" podcast.

Updated VIKTORIA-1 data show gedatolisib plus Faslodex, with or without Ibrance, improves progression-free survival in PIK3CA wild-type advanced breast cancer.

Cancer survivorship invites deeper questions about what we allow into our bodies, our homes, and the lives of those we love most.

Piqray plus Faslodex improved progression-free survival versus Faslodex alone in CDK4/6 inhibitor–pretreated, PIK3CA-mutated advanced breast cancer.

Dr. Roshani Patel answers questions from patients with breast cancer on Keytruda-induced colitis, sugar intake during chemo, and how to stay active.